Coronavirus pathogenesis in mice explains the SARS-CoV-2 multi-organ spread by red blood cell hitch-hiking

SARS-CoV-2 infection causes a multisystemic disease that affects numerous organs beyond the respiratory system. Thus, it is well known that COVID-19 is associated with a wide range of hematological disorders; however, it remains unclear how the SARS-CoV-2 virus is able to navigate from tissue to tissue. In this work, we performed a comprehensive analysis of the pleiotropic effects of a prototypical coronavirus in its natural host, the validated preclinical model of murine hepatitis virus (MHV). Throughout this study we compared our results with the real-world data from COVID-19 patients (including autopsies). Thus, the presence of viral RNA was only detected in less than 25% of the human serum samples, whereas all had multiple positive nasal swabs for SARS-CoV-2. Notably, we found viral RNA not only in lungs, but also in heart and kidney of deceased COVID-19 patients. Subsequently, we investigated the association between viral organotropism and clinical manifestations employing the MHV murine model. Results from RT-qPCR and viral infectivity showcased the presence of viral RNA and infectious particles in multiple organs including liver, lung, brain, heart, kidney, spleen and pancreas, and even the blood of infected mice. Surprisingly, when comparing plasma and red blood cells (RBCs)-enriched fraction, higher viral load levels were detected in RBCs, with decreased RBC count, and hematocrit and hemoglobin levels in infected mice. Next, we treated infected mice with hemin triggering more aggressive symptoms. Strikingly, when combining hemin treatment with chloroquine (a compound that known to interact with the heme group and induces a conformational change in its structure) the infection and its clinical manifestations were distinctly attenuated. Computational docking suggested that heme is able to bind to MHV Spike protein in a similar way to the one, experimentally observed for SARS-CoV-2. Overall, our results lead to a global perspective of COVID-19 beyond the canonical focus on the respiratory system, and strongly support the multi-organ extent of coronavirus infection through specific interactions with RBC hemoproteins.

[1]  J. F. Morton,et al.  Duration of viral infectiousness and correlation with symptoms and diagnostic testing in non-hospitalized adults during acute SARS-CoV-2 infection: A longitudinal cohort study , 2022, Journal of Clinical Virology.

[2]  S. Pittaluga,et al.  SARS-CoV-2 infection and persistence in the human body and brain at autopsy , 2022, Nature.

[3]  G. Lippi,et al.  Age, Sex and Previous Comorbidities as Risk Factors Not Associated with SARS-CoV-2 Infection for Long COVID-19: A Systematic Review and Meta-Analysis , 2022, Journal of clinical medicine.

[4]  D. Imhof,et al.  Host and viral proteins involved in SARS‐CoV‐2 infection differentially bind heme , 2022, Protein science : a publication of the Protein Society.

[5]  Ali I. Al-Gareeb,et al.  Hemolytic anemia in COVID-19 , 2022, Annals of Hematology.

[6]  Nicola Clementi,et al.  Unconventional CD147‐dependent platelet activation elicited by SARS‐CoV‐2 in COVID‐19 , 2021, Journal of Thrombosis and Haemostasis.

[7]  S. Bhatia,et al.  CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target , 2021, Science of The Total Environment.

[8]  M. Dimopoulos,et al.  Late‐onset hematological complications post COVID‐19: An emerging medical problem for the hematologist , 2021, American journal of hematology.

[9]  Thamil Vaani Komarasamy,et al.  Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword , 2021, Frontiers in Immunology.

[10]  Carolina Q. Sacramento,et al.  SARS-CoV-2 Proteins Bind to Hemoglobin and Its Metabolites , 2021, International journal of molecular sciences.

[11]  S. Soltani,et al.  Role of Glycoprotein Hemagglutinin-Esterase in COVID-19 Pathophysiology? , 2021, Stem Cell Reviews and Reports.

[12]  M. Malim,et al.  SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity , 2021, SciAdv.

[13]  R. Jayadevan,et al.  Long COVID: An overview , 2021, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[14]  M. Bollati-Fogolín,et al.  Ivermectin reduces in vivo coronavirus infection in a mouse experimental model , 2021, Scientific Reports.

[15]  M. Malim,et al.  SARS-CoV-2 recruits a haem metabolite to evade antibody immunity , 2021, medRxiv : the preprint server for health sciences.

[16]  Zhaohui Zheng,et al.  CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells , 2020, Signal Transduction and Targeted Therapy.

[17]  M. Marshall The lasting misery of coronavirus long-haulers , 2020, Nature.

[18]  K. Sahu,et al.  COVID‐19 related immune hemolysis and thrombocytopenia , 2020, Journal of medical virology.

[19]  E. Mahabir,et al.  Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2 , 2020, Viruses.

[20]  L. Platanias,et al.  Hematological manifestations of COVID-19 , 2020, Leukemia & lymphoma.

[21]  R. Romero-Ortuño,et al.  A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus? , 2020, International Journal of Antimicrobial Agents.

[22]  A. Korganow,et al.  Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine , 2020, Frontiers in Immunology.

[23]  X. Bian Autopsy of COVID-19 patients in China , 2020, National science review.

[24]  Á. Fajardo,et al.  Evaluation of SYBR Green real time PCR for detecting SARS-CoV-2 from clinical samples , 2020, bioRxiv.

[25]  H. Shan,et al.  Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19 , 2020, medRxiv.

[26]  H. Ulrich,et al.  CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement , 2020, Stem Cell Reviews and Reports.

[27]  Amber Dance What is a cytokine storm? , 2020 .

[28]  D. Raoult,et al.  New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? , 2020, International Journal of Antimicrobial Agents.

[29]  Sharon Einav,et al.  A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 , 2020, Journal of Critical Care.

[30]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[31]  S. Dahl The Role of Red Blood Cells in Hemostasis , 2016 .

[32]  S. Jeong,et al.  Loss of CD147 results in impaired epithelial cell differentiation and malformation of the meibomian gland , 2015, Cell Death and Disease.

[33]  S. Weiss,et al.  Expression of Hemagglutinin Esterase Protein from Recombinant Mouse Hepatitis Virus Enhances Neurovirulence , 2005, Journal of Virology.

[34]  N. Seidah,et al.  Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.

[35]  Fyaz M. D. Ismail,et al.  Mapping antimalarial pharmacophores as a useful tool for the rapid discovery of drugs effective in vivo: design, construction, characterization, and pharmacology of metaquine. , 2005, Journal of medicinal chemistry.

[36]  N. Surolia,et al.  Interaction of chloroquine and its analogues with heme: An isothermal titration calorimetric study. , 2000, Biochemical and biophysical research communications.

[37]  B. Maupin [Platelets and viruses]. , 1966, Hemostase.